Assessing Doximity After Prolonged Share Price Weakness

Doximity (DOCS) has seen its share price under pressure over the past year, with a negative 1 year total return and weaker performance in the past 3 months despite positive annual revenue and net income growth.

With the share price at $24.31, Doximity has experienced a sharp loss of momentum, with a 90 day share price return of 44.36% decline and a 1 year total shareholder return of 59.85% decline, pointing to weaker sentiment despite reported revenue and net income growth.

If you are reassessing Doximity and want to see how other healthcare focused AI names are trading, it may be worth scanning 36 healthcare AI stocks.

With Doximity trading at $24.31, a value score of 5, and both intrinsic and analyst target discounts implied, the key question is whether the recent share price slide leaves mispricing on the table or if the market already reflects its future growth.

Most Popular Narrative: 61.8% Undervalued

The most followed narrative values Doximity at $63.57 per share, well above the last close at $24.31, framing a wide valuation gap built on detailed earnings and margin assumptions.

The expanded adoption of AI-powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time, which in turn would support long-term revenue and margin expansion.

Curious what earnings path and margin profile support that higher fair value. The narrative leans on steady top line growth and premium profitability assumptions. Want to see how those moving parts stack up against that $63.57 figure.

Result: Fair Value of $63.57 (UNDERVALUED)

However, the narrative can still be knocked off course if free AI features take longer to monetize or if pharma marketing spend and regulation tighten more than expected.

Next Steps

With sentiment split between recent share price weakness and a bullish fair value, it makes sense to check the underlying data yourself and move quickly if it changes your view. To see what investors view as the key positives before deciding where you stand, review the 4 key rewards

Looking for more investment ideas?

If Doximity has you thinking harder about where to put fresh capital next, do not stop here. Broaden your watchlist with a few targeted stock ideas.

• Focus on fewer surprises and steadier profiles by scanning 69 resilient stocks with low risk scores which could help balance bolder positions in your portfolio.
• Look for stocks that combine quality with attractive entry points by reviewing the 61 high quality undervalued stocks before prices move away from you.
• Add potential early stage candidates to your radar by checking the 31 elite penny stocks with strong financials while they still sit off most investors' main screens.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.